We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Compugen and Merck Serono to Collaborate on Novel Peptide for the Treatment of Inflammatory Diseases

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Compugen Ltd. has announced that it has signed a collaboration agreement with Merck KGaA, acting for its pharmaceutical division Merck Serono, covering CGEN-855, a Compugen-discovered peptide targeting the FPRL1 G-protein coupled receptor (GPCR). This peptide has demonstrated, in recently completed initial in vitro and in vivo studies, the potential to treat, among other indications, inflammatory diseases.

The agreement covers additional research to be conducted by Compugen and provides Merck Serono with an option to exclusively license the novel peptide for worldwide development and commercialization.

Compugen also announced that CGEN-855 and supporting experimental data are the subject of an article newly published in the Journal of Pharmacology and Experimental Therapeutics.

“We are very proud to add Merck Serono to the growing list of leading pharma companies with which we have collaborations for the advancement of our product candidates,” said Compugen CEO Mr. Alex Kotzer. “We are also pleased to be the first Israeli biotech company that has signed an agreement with Merck Serono under the Global Enterprise Partnership program of the Chief Scientist of Israel.”

In addition to the GPCR Ligands Platform, Compugen now has two other platforms for predicting and selecting product candidates in this field: the DAC Peptide Blockers Discovery Platform and the Viral Peptides Discovery Platform.

To date, a number of interesting product candidates have been discovered and validated experimentally through the use of each of these platforms. These product candidates, including the CGEN-855 peptide now moving forward in collaboration with Merck Serono, target therapeutic areas with high clinical and commercial importance.